Illumisoft and CHAIR Plan Canadian Hospital Research Program to Evaluate SaniLume UV Device

Illumisoft Lighting Corp. Has collaborated with the Coalition for Community & Healthcare Acquired Infection Reduction (CHAIR) to develop plans for a Canadian hospital research program to evaluate its SaniLume upper-air ultraviolet disinfection device, the company said in a Newsfile release on October 28, 2026. The program is planned to comprise 13 linked studies, with studies targeted to begin in November 2026 subject to funding.

How the SaniLume Hospital Program Is Structured

CHAIR has entered into non-binding letters of intent with Shared Health and Winnipeg's Health Sciences Centre in Manitoba, and with the Provincial Health Services Authority in British Columbia, for planned facility-wide installations of SaniLume as part of the program. The program is designed to measure the effect of SaniLume on airborne pathogens, surface contamination and transmission of respiratory viral illness. It begins with two studies in partnership with the University of Waterloo: a bioaerosol chamber study comparing hospital ventilation rates with and without upper-air UV, and a computational fluid dynamics study of air movement in clinical spaces.

Under the proposed agreement, Illumisoft would provide SaniLume units for the planned installations and studies. The number of units, pricing and other terms have not yet been finalized. Illumisoft is not a party to the letters of intent, has not received any purchase orders in connection with the program and does not control the program or its timing. CHAIR does not receive any compensation from Illumisoft and does not hold any interest in Illumisoft.

SaniLume is a Health Canada-licensed, fan-assisted upper-air UV device manufactured by Illumisoft in Ottawa. In chamber testing at the University of Leeds, reported in August 2022 and commissioned and funded by Illumisoft, SaniLume reduced airborne concentrations of the test organisms (Staphylococcus aureus, Pseudomonas aeruginosa and the virus surrogate Phi-6 bacteriophage) by between 97% and 99.7%, depending on organism and device setting. Laboratory results do not establish performance in clinical settings, which the program is intended to evaluate.

"Our goal is to give hospitals a practical way to continuously disinfect the air while patients and staff remain in the room," said Ehsan Agahi, CEO of Illumisoft. "We have worked closely with CHAIR in developing this program. The proposed research is intended to help hospitals assess SaniLume's performance in clinical settings, understand its operational value and make informed decisions about potential broader adoption."

"We have engineered our way to cleaner rooms, cleaner sinks and cleaner surfaces," said Barry Hunt, Co-Founder and Executive Director of CHAIR. "Treating the air while patients and staff are in the room is the next step, and this program is designed to test whether upper-air UV can do that in real hospitals. We intend to begin the studies in November 2026, subject to funding being obtained."

Illumisoft Shares Gain DTC Eligibility

Illumisoft also said its common shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company, a subsidiary of DTCC. The company said DTC eligibility is expected to simplify the process of trading and enhance liquidity of its shares in the United States. Its shares recently began trading on the OTCQB Venture Market under the ticker symbol FUVCF, and trade on the TSX Venture Exchange under the symbol UVC.

November 2026 Study Start Targeted

CHAIR intends to begin the studies in November 2026, subject to funding, which has not yet been secured. Illumisoft expects to enter into an agreement with CHAIR for the provision of SaniLume units for the program.